|
Oct 3
|
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
|
|
Sep 30
|
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
|
|
Sep 27
|
How Many Stocks Should You Own?
|
|
Sep 27
|
Tempus AI expands oncology collaboration with Takeda
|
|
Sep 18
|
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
|
|
Sep 17
|
TAK vs. STVN: Which Stock Is the Better Value Option?
|
|
Sep 17
|
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
|
|
Sep 16
|
Vatroslav Mateljic Appointed General Manager of Takeda Canada
|
|
Jun 26
|
Takeda Announces New Assignments of Directors
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
Takeda reports positive data from Phase IIb trial of ITP treatment
|
|
Jun 24
|
EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
|
|
Jun 24
|
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
|
|
Jun 23
|
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
|
|
Jun 21
|
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
|
Jun 21
|
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
|
|
Jun 21
|
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
|
|
Jun 14
|
Takeda signs option agreement with Ascentage for CML drug
|
|
Jun 14
|
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
|
|
Jun 14
|
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
|